JetZero is thrilled to announce a significant milestone in its journey toward revolutionizing aviation, having successfully raised $235 million in funding. This infusion of capital will accelerate the development of JetZero's groundbreaking ultra-efficient Blended Wing Body jet, a project that promises to redefine performance and sustainability in the aerospace industry. In collaboration with key partners such as the US Air Force, NASA, and the FAA, JetZero is on track to bring this innovative aircraft to market by 2030. The Blended Wing Body design marks an unprecedented leap in commercial aircraft architecture, making it a pivotal step toward achieving zero-carbon emissions in aviation. The funding will be allocated towards advanced research and development initiatives, as well as refining the aircraft's design and performance capabilities. Notably, the JetZero aircraft will be 100% compatible with sustainable aviation fuel (SAF) and is designed with ample internal volume to accommodate zero-carbon hydrogen solutions. As the aerospace sector faces increasing pressure to reduce its environmental footprint, JetZero stands at the forefront of this imperative shift towards cleaner air travel. This funding announcement not only reinforces the company’s commitment to sustainability but also highlights the critical support from investors who share a vision for a sustainable aviation future. With this financial backing, JetZero is poised to lead the industry into a new era of eco-friendly flight, ensuring that the future of aviation is not only efficient but also aligns with global sustainability goals.
JetZero Secures $235 Million in Series A Funding to Revolutionize Commercial Aviation with Ultra-Efficient Blended Wing Body Jet
Get the full JetZero company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
EarthOptics
EarthOptics is transforming how the world understands and manages soil. By combining next-generation sensors, advanced algorithms, and carbon analytics, we’re building the Soil Cloud—a powerful data platform that empowers farmers to sustainably optimize their operations, increase yields, and feed a growing global population. Our technology delivers high-resolution insights into soil properties at scale, making a positive impact on both environmental health and farm profitability.
$110.0M Series c
today
Otomato.xyz
Meet your Smart DeFi assistant. One setup, zero dashboards. Get hyper-targeted updates on your positions, starting with HyperEVM. ✨
$2.0M Seed
today
Waypoint Bio
Waypoint Bio is a VC-backed biotech startup building the next generation of cell therapies for solid tumors.
$20.0M Series a
today
Crimson
Crimson’s IT recruitment services simplify the recruitment process, helping hiring managers find the best contract and permanent IT talent in established and emerging disciplines. Clients and candidates alike continue to choose Crimson because of three specific reasons: A commitment to keeping promises and delivering first time, supported by a £1M investment in relationship management technology. An unparalleled network and expert market insight from over 20 years’ sector experience. A world-beating level of friendly service borne out by a world-beating Net Promotor Score. Talk to us on 01675 466 477 and discover for yourself why candidates and hiring managers choose Crimson for their IT recruitment solutions.
$2.5M Seed
today
Asteromorph
We are a team of scientists and engineers working on building scientific superintelligence. Our discovery system - an orchestration of AI models designed to drive scientific progress as an independent architect - inspires breakthrough theses and develops them to robust statements with self-conducted experiments in both silicon and physical world.
$31.4M Seed
today
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | Waypoint Bio United States | Series a | $20.0M | today |
| 2 |  Default United States | Series a | $20.0M | today |
| 3 |  Abstract United States | Series a | $59.0M | 1d ago |
| 4 |  Pacifico Biolabs Germany | Series a | €7.0M | 1d ago |
| 5 |  Secretome Therapeutics United States | Series a | $30.0M | 1d ago |